16.45
-1.19 (-6.75%)
| Previous Close | 17.64 |
| Open | 17.54 |
| Volume | 85,523 |
| Avg. Volume (3M) | 140,470 |
| Market Cap | 720,464,000 |
| Price / Earnings (TTM) | 235.00 |
| Price / Sales | 243.28 |
| Price / Book | 2.32 |
| 52 Weeks Range | |
| Earnings Date | 14 May 2025 |
| Profit Margin | 31.01% |
| Operating Margin (TTM) | 29.97% |
| Diluted EPS (TTM) | 0.070 |
| Total Debt/Equity (MRQ) | 8.84% |
| Current Ratio (MRQ) | 16.10 |
| Operating Cash Flow (TTM) | 69.88 M |
| Levered Free Cash Flow (TTM) | 52.09 M |
| Return on Assets (TTM) | 23.07% |
| Return on Equity (TTM) | 34.38% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Maze Therapeutics, Inc. | Bullish | - |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 0.50 |
|
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 5.91% |
| % Held by Institutions | 92.25% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Foresite Capital Management Iv, Llc | 31 Mar 2025 | 2,111,919 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 34.00 (HC Wainwright & Co., 106.69%) | Buy |
| Median | 25.50 (55.02%) | |
| Low | 17.00 (Wedbush, 3.34%) | Buy |
| Average | 25.50 (55.02%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 16.35 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 23 Jul 2025 | 34.00 (106.69%) | Buy | 17.64 |
| Wedbush | 08 Jul 2025 | 17.00 (3.34%) | Buy | 15.06 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Aug 2025 | Announcement | Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights |
| 10 Jul 2025 | Announcement | Maze Therapeutics to Participate in Two Upcoming Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |